Hypertension Medications

	Hypertension Medications Hypertension In Children What Is Hypertension Sleep Apnea And Hypertension
	Hypertension And High Blood Pressure Cardiovascular Disease And Hypertension Hypertension Medications Salt And Hypertension Water Drinking And Hypertension Hypertension And Neck Pain
	High pressure inside the eye.

	Sodium Sensitivity of Blood Pressure in Chinese Populations This study indicated that approximately 39% of Chinese adults were sodium-sensitive. Sodium sensitivity was more common in women and in persons who were older and had higher usual blood pressure. Sodium sensitivity was also more common in individuals with higher responses to a cold pressor test and in individuals with the metabolic syndrome. Genetic factors may play an important role in determining sodium sensitivity in the Chinese population. A better understanding of the genetic and environmental determinants of sodium sensitivity has important public health and clinical implications. Content Type Journal ArticleDOI 10.1007/s11906-009-0088-4Authors Jing Chen, Tulane University School of Medicine Department of Medicine 1430 Tulane Avenue, SL45 New Orleans LA 70112 USA Jo... Carotid Baroreflex Activation: Past, Present, and Future Abstract  Electrical activation of the carotid baroreceptor system is an attractive therapy for the treatment of resistant hypertension. In the past, several attempts were made to directly activate the baroreceptor system in humans, but the method had to be restricted to a few selected patients. Adverse effects, the need for better electrical devices and better surgical techniques, and the lack of knowledge about long-term effects has greatly hampered developments in this area for many years. Recently, a new and promising device was evaluated in a multicenter feasibility trial, which showed a clinically and statistically significant reduction in office systolic blood pressure (>20 mm Hg). This reduction could be sustained for at least 2 years with an acceptable ... Recent Advances in Genetics of the Spontaneously Hypertensive Rat Abstract  The spontaneously hypertensive rat (SHR) is the most widely used animal model of essential hypertension and associated metabolic disturbances. Multiple quantitative trait loci associated with hemodynamic and metabolic parameters have been mapped in the SHR. Recently, it has become possible to identify some of the specific quantitative trait gene (QTG) variants that underlie quantitative trait loci linked to complex cardiovascular and metabolic traits in SHR related strains. Recombinant inbred strains derived from SHR and Brown Norway progenitors, together with SHR congenic and transgenic strains, have proven useful for establishing the identity of several QTGs in SHR models. It is anticipated that the combined use of linkage analyses and gene expression profiles, ... Darusentan in Resistant Hypertension: Lost in Translation Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s11906-009-0081-yAuthors Frank Enseleit, University Hospital Zurich Cardiovascular Center Cardiology Rämistrasse 100 8091 Zürich SwitzerlandFrank Ruschitzka, University Hospital Zurich Cardiovascular Center Cardiology Rämistrasse 100 8091 Zürich Switzerland Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 (Source: Current Hypertension Reports) Genome-Wide Association Studies: Contribution of Genomics to Understanding Blood Pressure and Essential Hypertension This article gives a short introduction to GWAS and summarizes the current findings for blood pressure and hypertension. Content Type Journal ArticleDOI 10.1007/s11906-009-0086-6Authors Georg B. Ehret, Johns Hopkins University Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine 733 N. Broadway Baltimore MD 21205 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 (Source: Current Hypertension Reports) Chronic Psychosocial Stress and Hypertension Abstract  Genetic and behavioral factors do not fully explain the development of hypertension, and there is increasing evidence suggesting that psychosocial factors may also play an important role. Exposure to chronic stress has been hypothesized as a risk factor for hypertension, and occupational stress, stressful aspects of the social environment, and low socioeconomic status have each been studied extensively. The study of discrimination is a more recent and rapidly growing area of investigation and may also help to explain the well-known racial disparities in hypertension. Research regarding mechanisms underlying stress effects on hypertension has largely focused on cardiovascular reactivity, but delayed recovery to the pre-stress level is increasingly being evaluated a... Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye Abstract  ?Wet? (also called neovascular) age-related macular degeneration (AMD) is a chronic progressive disease characterized by leakage of fluid or blood from choroidal neovascularization. It remains the leading cause of blindness in the developed world. Vascular endothelial growth factor (VEGF), which plays a key role in the pathogenesis of retinal neovascularization and vessel leakage leading to central vision loss, has emerged as a potential target in the treatment of wet AMD. Importantly, large-scale clinical trials have demonstrated that intravitreal VEGF antagonism prevents vision loss and may even improve visual acuity in patients with neovascular AMD. Because VEGF and its downstream mediator nitric oxide have a well-established cardioprotective role, however, ... Literature Alert Abstract  The beneficial effects of flavonoid consumption on cardiovascular risk are supported by mechanistic and epidemiologic evidence. We aimed to systematically review the effectiveness of different flavonoid subclasses and flavonoid-rich food sources on cardiovascular disease (CVD) and risk factors?ie, lipoproteins, blood pressure, and flow-mediated dilatation (FMD). Methods included a structured search strategy on MEDLINE, EMBASE, and Cochrane databases; formal inclusion or exclusion, data extraction, and validity assessment; and meta-analysis. One hundred thirty-three trials were included. No randomized controlled trial studied effects on CVD morbidity or mortality. Significant heterogeneity confirmed differential effects between flavonoid subclasses and foods. Choc... Novel Mechanisms for the Control of Renin Synthesis and Release Abstract  Renin is the key regulated step in the enzymatic cascade that leads to angiotensin generation and the control of blood pressure and fluid/electrolyte homeostasis. In the adult unstressed animal, renin is synthesized and released by renal juxtaglomerular cells. However, when homeostasis is threatened, the number of cells that express and release renin increases and extends beyond the juxtaglomerular area; the result is an increase in circulating renin and the reestablishment of homeostasis. The increase in the number of renin cells, a process termed recruitment, is achieved by dedifferentiation and re-expression of renin in cells derived from the renin lineage. The mechanisms that regulate the related processes of reacquisition of the renin phenotype, renin synthesi... Can Antihypertensive Treatment Reverse Large-Artery Stiffening? Abstract  In some controlled therapeutic trials for hypertension, a selective reduction of systolic blood pressure has been obtained with long-term treatment. The greatest effects on cardiovascular outcomes stem from a decrease of central blood pressure through a significant reduction of arterial stiffness, wave reflections, or both. Until now, all protocols have used angiotensin II blockade, mainly through angiotensin-converting enzyme inhibition. Cardiovascular outcomes have been significantly improved when compared with controls, but most of them have been treated with beta blockers. Such ?de-stiffening? therapies are important to consider and require additional trials. Content Type Journal ArticleDOI 10.1007/s11906-009-0085-7Authors Michel E. Safar, Centre de Di... Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension Abstract  The sympathetic nervous system plays an important role in circulatory and metabolic control and has clearly been established as a major contributor to the development of hypertension, as elevated sympathetic nerve activity initiates and sustains the elevation of blood pressure. Increased sympathetic outflow to the heart, resulting in increased cardiac output and neurally mediated vasoconstriction of peripheral blood vessels, is an obvious example of a neural pathophysiologic pathway leading to elevated blood pressure. The consequences of increased sympathetic outflow to the kidneys, perhaps most important in this context, are sodium and water retention, increased renin release, and alterations of renal blood flow?effects that contribute substantially to both acu... Control of hypertension in pregnancy Abstract  The hypertensive disorders of pregnancy are a leading cause of maternal mortality and morbidity. Complications are not limited to preeclampsia but also complicate both preexisting hypertension and isolated gestational hypertension. Blood pressure (BP) management is important but is only one aspect of management of the hypertensive disorders of pregnancy, which may be caused or exacerbated by underlying uteroplacental mismatch between maternal supply and fetal demand. BP treatment thresholds and goals vary in international guidelines, largely reflecting differences in opinion rather than differences in published data. Because of short-term maternal risks, there is consensus that BP should be treated when sustained at greater than or equal to 160 to 170 mm Hg systol... Myocardial remodeling in low-renin hypertension: Molecular pathways to cellular injury in relative aldosteronism Abstract  The pathologic hypertrophy of hypertensive heart disease is related to the quality, not the quantity, of myocardium; the presence of fibrosis is inevitably linked to structural and functional insufficiencies with increased cardiovascular risk. Elevations in plasma aldosterone that are inappropriate relative to dietary sodium, or relative aldosteronism, are accompanied by suppressed plasma renin activity, elevation in arterial pressure, and dyshomeostasis of divalent cations. The accompanying hypocalcemia, hypomagnesemia, and hypozincemia of aldosteronism contribute to the appearance of secondary hyperparathyroidism. Parathyroid hormone-mediated intracellular calcium overloading of cardiac myocytes and mitochondria leads to the induction of oxidative stress and mole... Seek and destroy: The ubiquitin-proteasome system in cardiac disease Abstract  The ubiquitin-proteasome system (UPS) is a major proteolytic system that regulates the degradation of intracellular proteins in the heart. The UPS regulates the turnover of misfolded and damaged proteins, in addition to numerous cellular processes, by affecting the stability of short-lived proteins such as transcription factors and cell signaling pathways. The UPS is tightly regulated by the specificity of ubiquitin ligases that recognize specific substrates and direct the addition of ubiquitin, targeting the substrates for degradation by the 26S proteasome. An increasing number of cardiac ubiquitin ligases have been identified, and the number of substrates each one is known to recognize also has increased, expanding their roles. Although mainly cardioprotective r... All things considered-including glucose control in the ICU Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0066-xAuthors Thomas R. Lux, The University of Texas Houston Medical School Department of Internal Medicine, Division of General Medicine Houston USAHeinrich Taegtmeyer, The University of Texas Houston Medical School Department of Internal Medicine, Division of Cardiology Houston USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 6 / December, 2009 (Source: Current Hypertension Reports) Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy Abstract  Doxorubicin (Dox) is a very potent anticancer agent, but its use is limited by its dose-dependent, irreversible cardiotoxicity. Despite intensive research efforts, the mechanism of Dox cardiotoxicity remains poorly understood, so very limited means are available for its prevention or effective management. Recent studies have revealed that a therapeutic dose of Dox can activate proteolysis in cardiomyocytes that is mediated by the ubiquitin-proteasome system (UPS), and that the UPS-mediated degradation of a number of pivotal cardiac transcription factors and/or survival factors is enhanced by Dox treatment. These findings suggest that Dox-induced UPS activation may represent a new mechanism underlying Dox cardiotoxicity. Notably, recent experimental studies suggest... Direct renin inhibition: An update Abstract  Aliskiren, the first orally effective direct renin inhibitor, is an effective antihypertensive agent with distinctive properties including placebo-like tolerability, pharmacologic effects that persist after drug discontinuation, and a unique mechanism of action. When combined with agents that inhibit the reninangiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or ?-blockers, additional blood pressure reduction reflects more complete RAAS blockade. Concern that marked elevation in plasma renin concentration following aliskiren administration might lead to RAAS-induced paradoxical blood pressure increases appears unfounded, based upon analyses of patients participating in clinical trials. Studies i... Cardiomyocyte autophagy: Remodeling, repairing, and reconstructing the heart Abstract  Autophagy is an evolutionarily conserved catabolic pathway of lysosome-dependent turnover of damaged proteins and organelles. When nutrients are in short supply, bulk removal of cytoplasmic components by autophagy replenishes depleted energy stores, a process critical for maintaining cellular homeostasis. However, prolonged activation of autophagic pathways can result in cell death. Longstanding evidence has linked the stimulation of lysosomal pathways to pathologic cardiac remodeling and a number of cardiac diseases, including heart failure and ischemia. Only recently, however, has work begun to parse cytoprotective autophagy from autophagy that contributes to disease pathogenesis. Current thinking suggests that the effects of autophagy exist on a continuum, with... Recommendations for global hypertension monitoring and prevention Abstract  In recent years, cardiovascular diseases (CVDs) have been recognized as the most common cause of death in the world, accounting for 30% of all mortality, with a growing burden in developing countries. In 2000, it was estimated that 26% of the world?s adult population (972 million individuals) had prevalent hypertension, a key risk factor for CVD, and this number is expected to increase to 29% (1.56 billion) by 2025. CVDs place a heavy burden on society and overall economic activity; they are ranked third in disability-adjusted life years lost. We now have a comprehensive understanding of the basic lifestyle modifications that decrease risk of hypertension and its associated sequelae, however, and it is clear that only modest lifestyle changes would be required t... WNK kinases and blood pressure control This article reviews current knowledge of the role of these proteins in ion homeostasis and volume control. Content Type Journal ArticleDOI 10.1007/s11906-009-0072-zAuthors Staci L. DeatonSamarpita SenguptaMelanie H. Cobb, University of Texas Southwestern Medical Center Department of Pharmacology 6001 Forest Park Road Dallas TX 75390 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 6 / December, 2009 (Source: Current Hypertension Reports) Trends in hypertension treatment in diabetes Abstract  This review discusses current concepts and future trends in the optimal control of elevated blood pressure and hypertension in persons with diabetes, specifically type 2 diabetes mellitus. Although the primary management for persons with type 2 diabetes mellitus, especially with lower levels of blood pressure elevation, is modification or reversal of adverse lifestyles, including weight management and increased physical activity, pharmacologic antihypertensive treatment is usually necessary to optimally control cardiovascular and renal risks. Therapies that modulate the renin-angiotensin-aldosterone system may be beneficial in reducing associated cardiovascular and renal diseases, but control of elevated blood pressure remains an essential target of any antihypert... Aldosterone and cardiovascular risk Abstract  Through its classic effects on sodium and potassium homeostasis, aldosterone, when produced in excess, is associated with the development of hypertension and hence with higher cardiovascular and renal risk. In recent years, experimental and epidemiologic data have suggested that aldosterone also may be linked to high cardiovascular risk independently of its effects on blood pressure. Thus, aldosterone has been associated with obesity and metabolic syndrome in selected populations, and these associations may further contribute to the higher cardiovascular risk of subjects with elevated aldosterone levels. Moreover, aldosterone has been reported to promote inflammation, oxidative stress, and fibrosis in a number of tissues. Clinical evidence indicates that patients ... Literature alert Content Type Journal ArticleDOI 10.1007/s11906-009-0067-9 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 6 / December, 2009 (Source: Current Hypertension Reports) Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy Abstract  Proteinuria is both a marker and a mediator of progressive renal damage; higher levels are associated with greater cardiovascular and renal risk. At normal and low levels of proteinuria (in the microalbuminuria range), the rate of hard renal events (dialysis and doubling of creatinine) is much lower than the mortality rate. At higher levels of proteinuria, the renal event rate surpasses the mortality rate. In the overt nephropathy range (proteinuria > 0.5 g/L), patients who achieve lower proteinuria with therapy have improved hard renal outcomes, but this result has not been demonstrated in the microalbuminuria range. For patients with more severe overt nephropathy, there is a basic rationale for additional blockade of the renin-angiotensin-aldosterone system (... Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg? Abstract  Current guidelines recommend a blood pressure goal of less than 130/80 mm Hg in patients with chronic kidney disease. Considerable epidemiologic observational data, post hoc analyses of clinical trials, and meta-analyses support this goal, particularly in patients with proteinuria. Although prospective clinical trials have not shown a clear benefit, recent data indicate that a longer duration of follow-up may be needed to assess the effects of different blood pressure goals. While we await the results of several ongoing and planned studies in this area, the current recommendations of a blood pressure goal less than 130/80 mm Hg appear reasonable. Content Type Journal ArticleDOI 10.1007/s11906-009-0060-3Authors Bassam G. Abu JawdehMahboob Rahman, University Hos... Hypertension in children and adolescents: An approach to management of complex hyper tension in pediatric patients Abstract  Although primary (essential) hypertension is detectable in childhood, secondary causes of hypertension must be considered in evaluating and managing hypertension in children and adolescents. Very young children and children with severe hypertension may have an underlying cause of the hypertension. Interventions to control elevated blood pressure (BP) are clinically important for all children with high BP. Nonpharmacologic approaches are recommended for all asymptomatic children with hypertension and prehypertension. Some children and adolescents will require pharmacologic therapy to control BP and to optimize organ protection. Recent advancements in pediatric clinical trials of antihypertensive agents have provided data on BP-lowering effects and safety in childre... Hypertension in patients with chronic kidney disease Abstract  Hypertension is very common in patients with chronic kidney disease (CKD); it causes early loss of kidney function and accelerated cardiovascular morbidity and mortality. African American patients with hypertension and genetic disposition are at an even higher risk for renal disease and ultimately renal failure. Hypertensive patients with CKD should aim for stringent blood pressure (BP) control (target < 130/80 mm Hg) requiring more than one drug with renin-angiotensin-aldosterone system blockade as a component of therapy targeting both hyper tension and proteinuria. Management of hypertension in the dialysis population should focus on ambulatory measurements of BP and the use of longer-acting antihypertensive drugs, with their dosage and timing adjusted accord... Home blood pressure monitoring to manage hypertension in patients with nephropathy: The time has arrived Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0063-0Authors George Bakris, 5841 South Maryland Avenue, MC 1027 Chicago IL 60637 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Hypertension Reports) Hypertension guidelines and chronic kidney disease: Physicians, please follow directions Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0064-zAuthors George Bakris, 5841 South Maryland Avenue, MC 1027 Chicago IL 60637 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Hypertension Reports) Hypertension: Issues in control and resistance Abstract  Hypertension remains uncontrolled in more than 50% of treated patients. Barriers to hypertension control include those that are patient-related, physician-related, and related to the health system. Identification of uncontrolled hypertension, pseudoresistant hypertension, and resistant hypertension require thoughtful attention to accurate blood pressure measurement, lifestyle factors, evaluation for secondary causes of hypertension, and proper treatment. Recent guidelines emphasize the importance of aggressive treatment and referral to hypertension specialists for patients with resistant hypertension, defined as blood pressure that remains above goal despite the use of three appropriate anti hypertensive agents. Content Type Journal ArticleDOI 10.1007/s11906-009... Effect of blood pressure lowering on markers of kidney disease progression Abstract  Hypertension remains a common comorbidity and cause of chronic kidney disease (CKD). As the number of patients with CKD grows, so does the need to identify modifiable risk factors for CKD progression. Data on slowing progression of CKD or preventing end-stage renal disease with aggressive blood pressure control have not yielded definitive conclusions regarding ideal blood pressure targets. Shifting the focus of antihypertensive therapy to alternative markers of end-organ damage, specifically proteinuria, has yielded some promise in preventing the progression of CKD. Nevertheless, proteinuria and decline in estimated GFR may represent an irreversible degree of injury to the kidney that limits the impact of any therapy. The identification and use of novel markers of... Treatment of hypertensive urgencies and emergencies Abstract  Although systemic hypertension is a common clinical condition, hypertensive emergencies are unusual in clinical practice. There are some situations, however, that qualify as hypertensive emergencies or urgencies. It is important, therefore, to diagnose these acute conditions, in which immediate treatment of hypertension is indicated. The diagnosis of hypertensive emergencies depends on consideration of the clinical manifestations as well as the absolute level of blood pressure. Manifestations of hypertensive emergencies can be quite profound, but they vary depending on the target organ that is affected. Thus, an accurate clinical diagnosis is necessary to render appropriate therapy. Fortunately, effective drug therapy is available to lower the blood pressure quick... Blood pressure control in the elderly: Can you have too much of a good thing? Abstract  Hypertension (especially systolic hypertension) is very common in older persons. Systolic hypertension occurs because large conduit arteries become stiffer with age. Strong evidence from randomized trials suggests that treating systolic blood pressures initially higher than 160 mm Hg is extremely beneficial, and a recent trial extended this conclusion to healthy persons over 80 years of age. However, the only trial that has directly tested the use of more aggressive treatment goals (< 140 mm Hg) in the elderly did not show benefit in those older than 75. Risks of overtreating hypertension for the elderly include falls and orthostatic hypotension, and the most compromised older persons may be the most likely to experience adverse effects. Our current state of kn... Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney? Abstract  Inhibition of the renin-angiotensin system contributes to reductions in proteinuria and in progression of chronic kidney disease. Indeed, monotherapy with either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) has been shown to decrease proteinuria and slow the decline of chronic kidney disease, but incompletely. Therefore, there is increasing interest in whether combination strategies will provide more complete blockade of the renin-angiotensin system, which may translate into superior renoprotective and cardioprotective effects compared with either agent alone. There have been several reports on combination strategies. However, the recent report of the Ongoing Telmisartan Alone and in Combination with Ramipril Global End... Should albuminuria be a focus of antihypertensive therapy goals? Abstract  Albuminuria has been recognized as a risk marker for both chronic kidney disease and cardiovascular disease in large observational cohorts. In addition, post hoc analyses of many large randomized trials have found a positive relationship between albu minuria and adverse renal and cardiovascular outcomes, leading some to suggest that albuminuria may be a potential therapeutic target for antihypertensive treatment. However, direct clinical evidence linking albuminuria reduction to reduction in adverse renal and cardiovascular events is scarce. This paper reviews the evidence in the current literature to address whether albuminuria can be used as a credible predictor of risk for chronic kidney disease and cardiovascular disease and also reviews the clinical trial evi... Literature alert Content Type Journal ArticleDOI 10.1007/s11906-009-0065-y Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Hypertension Reports) Therapeutic approaches to diastolic dysfunction Abstract  Progressive abnormalities of passive stiffness or active relaxation of the myocardium that impair ventricular filling during diastole may be an important contributor to the development of heart failure in patients with preserved ejection fraction. In this review, we discuss the epidemiology and pathophysiology of diastolic dysfunction and heart failure with preserved ejection fraction, highlighting potential therapeutic approaches and exploring the limited available evidence base for improving clinical outcomes in patients with these challenging entities. Content Type Journal ArticleDOI 10.1007/s11906-009-0048-zAuthors Rajesh JanardhananAkshay S. DesaiScott D. Solomon, Brigham and Women?s Hospital Cardiovascular Division 75 Francis Street Boston MA 02115 USA ... The role of peroxisome proliferator-activated receptor ? in blood pressure regulation Abstract  Peroxisome proliferator-activated receptor-? (PPAR?) is a member of the nuclear hormone receptor superfamily. It is expressed in adipocytes, immune cells, and cardiovascular cells that include cardiomyocytes, endothelial cells, and smooth muscle cells. PPAR? plays a role in regulating cellular anti-inflammatory responses and is a mediator of insulin sensitization induced by thiazolidinediones, which also can reduce elevated blood pressure both clinically and experimentally. As a result, research regarding the role of PPAR? in blood pressure homeostasis is ongoing. Recent studies have demonstrated that increases or decreases in blood pressure phenotype may be PPAR?-dependent and involve a number of different signaling pathways. Furthermore, studies using PPAR?.. Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PRoFESS trial This article examines the cerebrovascular protection provided by antihypertensive drug treatment in the light of the results of recent meta-analyses and of the findings of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. Content Type Journal ArticleDOI 10.1007/s11906-009-0045-2Authors Guido Grassi, Ospedale San Gerardo Clinica Medica Via Pergolesi 33 20052 Monza (Milan) ItalyFosca Quarti-TrevanoRaffaella Dell?OroGiuseppe Mancia Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Hypertension Reports) Management of hypertension in hemodialysis patients Abstract  Hypertension is very common in patients with chronic kidney disease and is present in most patients with end-stage renal disease (ESRD). Hypertension is largely responsible for premature cardiovascular disease in dialysis patients. The pathophysiology of hypertension in ESRD is complex, and multiple mechanisms are likely involved in blood pressure dysregulation in patients on hemodialysis. Some of these patients demonstrate resistant hypertension. Aggressive control of hypertension in ESRD/dialysis is mandatory. Generally, nonpharmacologic treatments are not enough to achieve the goal blood pressure levels in dialysis patients. Multiple antihypertensive drugs are often necessary. Drugs that block the reninangiotensin system offer a number of advantages for patient... Hypertension, dementia, and antihypertensive treatment: Implications for the very elderly Abstract  A wealth of longitudinal epidemiologic evidence links high blood pressure or hypertension to cognitive decline and incident dementia. Some (but not all) studies have suggested that antihypertensive treatment is beneficial, reducing risk of decline and dementia. There are plausible mechanisms to support the possibility that hypertension may increase the risk of dementia. There is also evidence suggesting that the two dementia types thought to be most common, Alzheimer?s disease and vascular dementia, have overlapping risk factors. Seven placebo-controlled trials of antihypertensive treatment have assessed cognitive function, incident dementia, or both, with mixed outcomes. The Hypertension in the Very Elderly Trial (HYVET), despite showing reductions in mortality... Antihypertensive drugs and central blood pressure Abstract  Recent evidence suggests that central blood pressure is a more important determinant of cardiovascular risk than brachial pressure. Interestingly, antihypertensive drugs exert different effects on brachial and central pressure. Traditional ?-blockers, such as atenolol, appear to have an adverse impact on central pressure, despite lowering brachial pressure. This may help to explain the results of recent large outcome studies using atenolol. Further research is required to clarify whether other antihypertensive agents lower central pressure beyond the effects observed on brachial pressure. Content Type Journal ArticleDOI 10.1007/s11906-009-0043-4Authors Carmel M. McEniery, University of Cambridge, Addenbrooke?s Hospital Clinical Pharmacology Unit Box 110 Camb... Treatment of hypertension in patients with peripheral arterial disease: An update Abstract  Hypertension is a known risk factor for cardiovascular events, and recent data have pointed to peripheral arterial disease (PAD) as another strong risk factor; together, they cause a surprisingly high total risk. This review deals with the clinical management of this dangerous association. The ankle-brachial index helps in the diagnosis of PAD and the estimation of risk. To control risk, lifestyle adaptation is essential. There is no consensus on a first choice of antihypertensive drug. Arguments favor angiotensin-converting enzyme inhibitors, but most patients require several antihypertensive drugs to reach goal pressure (140/90 mm Hg or lower). Moreover, to control the risk of PAD, antiplatelet drugs, antihypertensive drugs, and statins are recommended. Conte... Choosing the ideal drug for hypertension after ischemic stroke This article reviews the studies assessing the efficacy of each agent class in secondary stroke prevention. The comparison of studies and agents is often difficult because of differences in achieved blood pressures and in the exact agents and combinations of agents that are used. Meta-analysis has attempted to resolve some of these difficulties by using meta-regression modeling to predict ?expected? risk reduction given an achieved blood pressure. The resultant ability to give a value to ?blood pressure-independent? effects is questioned. The effect of reducing blood pressure far outweighs any other effect in reducing stroke risk, and the agent that has been shown to be most consistently equal or superior to any agent compared with it has been amlodipine, a calcium-channel bl... ACCOMPLISH the goal: Hypertension and beyond Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0050-5Authors Helmy M. Siragy, University of Virginia School of Medicine the Department of Medicine and Hypertension Center Charlottesville Virginia USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Hypertension Reports) The SANDS Randomized Trial Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0052-3Authors Thomas D. Giles, Tulane University School of Medicine the Department of Medicine, Section of Cardiology New Orleans USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Hypertension Reports) The potential role of the angiotensin subtype 2 receptor in cardiovascular protection Abstract  Advances in our knowledge of the renin-angiotensin system have led to better understanding of the mechanisms contributing to the development of cardiovascular, renal, and metabolic disorders. Similarly, the discovery of new components of this system offers opportunities to develop new therapeutic tools to manage these diseases. Angiotensin subtype 2 (AT2) receptor represents one of those components with the potential for improving cardiovascular protection. Current knowledge suggests that the AT2 receptor antagonizes the effects of the angiotensin subtype 1 receptor. AT2 receptor activation is linked to vasodilation, nitric oxide production, and antiproliferative and anti-inflammatory effects. The role of the AT2 receptor in inducing natriuresis, inhibiting renin ... Literature alert Content Type Journal ArticleDOI 10.1007/s11906-009-0051-4 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Hypertension Reports) Antihypertensive drugs with anti-inflammatory properties are more effective in treating postmenopausal hypertensive women Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0029-2Authors Kathleen H. Berecek Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Hypertension Reports) Sympathoadrenal mechanisms in the pathogenesis of sleep apnea-related hypertension Abstract  Obstructive sleep apnea-hypopnea (OSAH) is regarded as an increasingly common cause of sustained hypertension. The vast majority of mechanistic studies linking these entities have focused on the role of sympathoactivation. This review therefore addresses this purported mechanism by highlighting studies conducted in the past 5 years that speak to OSAH-related changes in sympathoregulation, independent of obesity, as well as the intervening players and pathways that may be relevant to such changes. Finally, studies with a focus on changes in sympathoregulation induced by continuous positive airway pressure (CPAP) therapy are discussed. Taken together, these findings strengthen the claim that the sympathoadrenal pressor system is essential for the development of the ... Left ventricular hypertrophy and renin-angiotensin system blockade Abstract  The renin-angiotensin system (RAS), an important control system for blood pressure and intravascular volume, also causes left ventricular hypertrophy (LVH) and fibrosis. The main causal mechanism is the increase in blood pressure, which leads to increased left ventricular wall stress; however, aldosterone release from the adrenals and (more controversially) the direct action of angiotensin II on the cardiomyocytes also play a role. Large clinical trials evaluating the blockade of the RAS with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have demonstrated an ability to prevent progression and induce regression of left ventricular mass, thereby reducing the significant and independent cardiovascular risk conferred by LVH. Regression of l... Central blood pressure, arterial stiffness, and wave reflection: New targets of treatment in essential hypertension Abstract  Central blood pressure is dependent on the stiffness of large arteries and pulse wave reflection. These parameters are very important in the development of hypertensive target organ disease. Moreover, recent clinical studies have shown their independent predictive value for cardiovascular morbidity and mortality. Therefore, 2007 guidelines for the management of hypertension inserted the evaluation of central arterial stiffness as an important component for assessing total cardiovascular risk. Differences in the way various antihypertensive drugs affect arterial stiffness and central hemodynamics may explain the greater cardiovascular protection provided by newer drugs (eg, renin-angiotensin system blockers or calcium channel blockers) independent of peripheral blo... The role of cardiac autonomic function in hypertension and cardiovascular disease Abstract  Autonomic nervous system abnormality, clinically manifested as a hyperkinetic circulation characterized by elevations in heart rate, blood pressure, plasma norepinephrine levels, and cardiac output, has been repeatedly demonstrated in hypertension. Increased release of norepinephrine from the brain has also been described in hypertension, and increased sympathetic activity has been demonstrated using spectral analysis of heart rate variability, particularly in the early stage of hypertension and in white-coat hypertension. Studies performed with microneurographic assessment also have found a marked increase in muscle sympathetic nervous activity in subjects with both borderline and established hypertension. A transition from the early hyperkinetic state to a high-... Central mineralocorticoid receptors, sympathetic activity, and hypertension This article reviews some of the recent advances in this area, particularly mechanisms by which the mineralocorticoid receptor maintains selectivity for its ligand within the central nervous system, its role in salt appetite, and the possibility of local production of corticosteroids. In addition, the links between central mineralocorticoid receptor activation, stress, sympathetic activity, and hypertension are discussed. Content Type Journal ArticleDOI 10.1007/s11906-009-0039-0Authors Frances McManusScott M. MacKenzieE. Marie Freel, University of Glasgow BHF Glasgow Cardiovascular Research Centre 126 University Place Glasgow G12 8TA UK Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Numb... The macrocirculation and microcirculation of hypertension Abstract  Changes in vascular structure that accompany hypertension may contribute to hypertensive end-organ damage. Both the macrovascular and microvascular levels should be considered, as interactions between them are believed to be critically important. Regarding the macrocirculation, the article first reviews basic concepts of vascular biomechanics, such as arterial compliance, arterial distensibility, and stress-strain relationships of arterial wall material, and then reviews how hypertension affects the properties of conduit arteries, particularly examining evidence that it accelerates the progressive stiffening that normally occurs with advancing age. High arterial stiffness may increase central systolic and pulse pressure by two different mechanisms: 1) Abnormally h... The role of the sympathetic nervous system in obesity-related hypertension Abstract  Obesity is recognized as a major health problem throughout the world. Excess weight is a major cause of increased blood pressure in most patients with essential hypertension and greatly increases the risk for diabetes, cardiovascular diseases, and end-stage renal disease. Although the mechanisms by which obesity raises blood pressure are not completely understood, increased renal sodium reabsorption, impaired pressure natriuresis, and volume expansion appear to play important roles. Several potential mechanisms have been suggested to contribute to altered kidney function and hypertension in obesity, including activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system, as well as physical compression of the kidneys, especially when vi... Differential diagnosis of primary aldosteronism subtypes This article reviews the strategies to correctly identify PA subtypes, underlining the central role of adrenal vein sampling. Content Type Journal ArticleDOI 10.1007/s11906-009-0038-1Authors Paolo Mulatero, AOU San Giovanni Battista Division of Internal Medicine and Hypertension Via Genova 3 10126 Torino ItalyChiara BertelloAndrea VerhovezDenis RossatoGiuseppe GiraudoGiulio MengozziGiorgio LimeruttiEleonora AvenattiDavide TizzaniFranco Veglio Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Hypertension Reports) Literature alert Content Type Journal ArticleDOI 10.1007/s11906-009-0040-7 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Hypertension Reports) Hypertension and the bradykinin system Abstract  The blood pressure-lowering property of the brady kinin system has been documented for more than eight decades. The bradykinin system is involved in the mediation and modulation of the vasoconstrictor renin-angiotensin system and the vasodilators prostaglandin, prostacyclin, and nitric oxide in regulating sodium water balance, renal and cardiac hemodynamics, and blood pressure. Reduced activity of the bradykinin system has been observed in various hypertensive situations in both clinical and experimental models of hypertension. Antihypertensive properties of the angiotensin-converting enzyme or kininase II inhibitors are primarily mediated via the bradykinin-releasing pathway, which may also cause regression of left ventricular hypertrophy in hypertensive situatio... The crumbling of dual renin-angiotensin system blockade Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0028-3Authors Franz H. Messerli Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Hypertension Reports) Strategies for managing perioperative hypertension This article reviews perioperative hypertension emergencies/urgencies and various approaches for management. Content Type Journal ArticleDOI 10.1007/s11906-009-0031-8Authors Ronak G. DesaiMuhammad MuntazarMichael E. Goldberg, Cooper University Hospital, UMDNJ/Robert Wood Johnson Medical School Department of Anesthesiology Camden Campus Camden NJ 08103 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Hypertension Reports) Ethnic, gender, and age-related differences in patients with the metabolic syndrome Abstract  The metabolic syndrome is a clustering of cardiovascular risk factors and is associated with an increased risk of developing diabetes, cardiovascular disease, and kidney disease. Epidemiologic studies have demonstrated differences in prevalence by age, gender, and ethnicity. The prevalence of the metabolic syndrome increases with age through the sixth decade of life among men and seventh decade among women. Most, but not all, studies reported a higher prevalence of the metabolic syndrome among women compared with men. Although the metabolic syndrome is more common among Mexican Americans compared with non-Hispanic whites and blacks, among men the metabolic syndrome is more common among non-Hispanic whites than non-Hispanic blacks; the reverse is true among women. ... Albuminuria: What can we expect from the determination of nonimmunoreactive albumin? Abstract  Albuminuria is an early marker for diabetic nephropathy in patients with diabetes, and has a clear place in patient care. It also predicts cardiovascular events and mortality in diabetic patients and in the general population, and is slowly becoming accepted in population screening for cardiovascular disease and chronic kidney disease. Recently, investigators found that a considerable amount of albumin in urine is nonimmunoreactive and that classic immunochemical assays do not properly measure all albumin in urine. Assays that detect immunoreactive plus nonimmunoreactive albumin may better predict development of diabetic nephropathy, cardiovascular events, and mortality than assays that only detect immunoreactive albumin. Proof of the existence of nonimmunoreactiv... Aortic stiffness, kidney disease, and renal transplantation Abstract  In subjects with chronic kidney disease (CKD), treatment of high systolic blood pressure is a key element in preventing disease progression and the occurrence of cardiovascular (CV) events. This relationship between the large arterial system and kidney function was demonstrated in different renal populations. In subjects with mild to severe renal insufficiency, increased aortic stiffness and reduced creatinine clearance are closely related and are independent of traditional CV risk factors. In renal transplant patients, aortic stiffness is significantly increased irrespective of donor type. Donor age and/or acute rejection contribute independently to the increased stiffness. In the presence of renal dysfunction, an increase in systemic pulse pressure frequently ma... Effect of excessive salt intake: Role of plasma sodium Abstract  Sodium chloride is a normal and necessary constituent of food and the main cause for the rise in arterial pressure that occurs with age. Changes in dietary salt intake can cause changes in plasma sodium. Even a small increase has been shown to be harmful, for example, by increasing left ventricular mass, thickening and narrowing resistance arteries, and stiffening endothelial cells. Therefore, it is possible that an increase in plasma sodium is an important pressor mechanism. This review discusses the role of dietary sodium and plasma sodium, with a special focus on their impact on the endothelial cell. Content Type Journal ArticleDOI 10.1007/s11906-009-0018-5Authors Stefan ReuterEckhart BüssemakerMartin HausbergHermann PavenstädtUta Hillebrand, Medizinische ... ONTARGET: Does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0017-6Authors Jean-Michel HalimiAlbert Mimran Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Hypertension Reports) Intensified inhibition of renin-angiotensin system: A way to improve renal protection? Abstract  Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have clearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal... The intracellular renin-angiotensin system in the heart We describe the physiology of the intracellular RAS, potential pathologic roles of intracellular Ang II, and the relevance of the intracellular system in view of recent clinical trials involving various RAS inhibitors. Content Type Journal ArticleDOI 10.1007/s11906-009-0020-yAuthors Rajesh KumarVivek P. SinghKenneth M. Baker, 1901 South First Street, Building 205 Temple TX 76504 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Hypertension Reports) Literature alert Content Type Journal ArticleDOI 10.1007/s11906-009-0015-8 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Hypertension Reports) Weight loss maintenance: An excellent approach to control hypertension but a difficult goal to reach Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0016-7Authors Efrain Reisin Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Hypertension Reports) Ambulatory blood pressure monitoring in childhood and adult obesity Abstract  Body mass and body fat are known modulators of blood pressure (BP) measured by clinic sphygmomanometry. However, the ambulatory BP-monitoring characteristics unique to obesity have not been widely studied. We reviewed the literature on ambulatory BP monitoring for links between measures of body adiposity in lean and overweight children and adults and various BP measures obtained by ambulatory monitoring. Collectively, the findings suggest significant associations of adiposity with ambulatory BP and heart rate, sleep-related BP dipping, and the white-coat phenomenon. Content Type Journal ArticleDOI 10.1007/s11906-009-0024-7Authors Iddo Z. Ben-DovMichael Bursztyn, Hadassah-Hebrew University Medical Center Department of Internal Medicine, Hypertension Unit Mount S... The role of statins in the treatment of the metabolic syndrome Abstract  The metabolic syndrome is a cluster of cardiometabolic risk factors associated with higher risk for atherosclerotic cardiovascular (CV) disease and diabetes. Its prevalence is about 20% to 30% among adults worldwide and is increasing. The primary goal is reduction of CV risk through lifestyle changes and drug therapy if required. Post hoc analyses of prospective trials showed the benefit of lowering low-density lipoprotein (LDL) cholesterol in patients with the metabolic syndrome. Statin therapy exerts beneficial effects not only by lowering LDL cholesterol but also via its so-called pleiotropic effects. These effects seem particularly important for reducing risk of CV disease in patients with the metabolic syndrome. Thus, evidence is accumulating that statins are... Update on the metabolic syndrome: Hypertension Abstract  The presence of the metabolic syndrome identifies an individual at increased risk for diabetes, cardiovascular disease, and early mortality. However, the increased risk may vary by the absence or presence of hypertension. Current guidelines for the management of high blood pressure in the metabolic syndrome emphasize lifestyle modification as a first-line strategy. Pharmacologic treatment of elevated blood pressure in the metabolic syndrome may be necessary in the presence of other cardiovascular risk factors or to achieve adequate blood pressure control. Currently, there is no consensus as to which antihypertensive therapy should be used to treat hypertension in patients with the metabolic syndrome; it remains unclear whether achieving tight blood pressure contro... The metabolic syndrome: Insulin resistance Abstract  Insulin resistance is the most accepted unifying theory explaining the pathophysiology of the metabolic syndrome. However, epidemiologic studies indicate that a substantial proportion of patients with the metabolic syndrome do not have evidence of insulin resistance, and the correlation between insulin resistance and individual components of the syndrome is weak to moderate. Insulin resistance may play an important role in the development of hyperglycemia and dyslipidemia, which can further aggravate insulin resistance. The implication of insulin resistance in hypertension appears to be less strong than its role in causing hyperglycemia and dyslipidemia. Obesity may be another pathogenic factor in the metabolic syndrome that may help initiate or worsen insulin res... Stress-induced sodium retention and hypertension: A review and hypothesis Abstract  Hypertension?an important health problem in industrialized nations?is particularly significant in blacks and obese individuals, in whom it is hypothesized to result from impaired renal sodium regulation. We reviewed studies that identified individuals with impaired sodium regulation by examining the natriuretic response to mental stress. A significant percentage of black and obese individuals retain or have a diminished natriuretic response to mental stress despite increased blood pressure (BP). This contributes a volume component to the normal resistance-mediated BP increase, and BP remains elevated after the stressor ceases until the volume expansion diminishes. The stress exposes these individuals to greater cardiovascular load. This response pattern has be... Heme oxygenase and renal disease Abstract  The cellular content of heme, derived from the breakdown of heme proteins, is regulated via the heme oxygenase (HO) enzyme system. HO catalyzes the rate-limiting step in heme degradation resulting in the formation of iron, carbon monoxide, and biliverdin. Recent studies have focused on the biologic effects of product(s) of this reaction, which have important antioxidant, antiapoptotic, anti-inflammatory, and cytoprotective properties. Two isoforms of the HO enzyme have been described: an inducible isoform (HO-1) and a constitutively expressed isoform (HO-2). Induction of HO-1 occurs as a beneficial response to several injurious stimuli and has been implicated in many clinically relevant disease states including sepsis, hypertension, atherosclerosis, and acute lung... Baroreflex device therapy in the treatment of hypertension Abstract  Despite therapy with multiple optimally dosed medications, hypertension remains poorly controlled in a sizeable number of people worldwide. This has spurred interest in exploring other pharmacologic and nonpharmacologic options for treatment. The carotid baroreceptors are important in regulating blood pressure in chronic hypertension by centrally mediated sympathoinhibitory effects and other effects. This has led to renewed interest in treating hypertension by electrically stimulating the carotid baroreceptors. Although this concept was first studied several decades ago, modern technology and better understanding of physiology have finally allowed the development of a feasible treatment option. Ongoing trials are finding significant and sustained reductions in blo... The role of incretins in cardiovascular control Abstract  Glucagon-like peptide-1 (GLP-1) is an incretin secreted in response to nutrient ingestion. Understanding the incretin effect on diabetes pathophysiology has led to development of a new class of agents termed incretin mimetics. Exenatide is the first GLP-1 agonist approved to treat type 2 diabetes mellitus (T2DM). Clinical studies have demonstrated exenatide?s efficacy in improving glycemic control, often coupled with weight loss. Studies are investigating the potential cardiovascular benefits of GLP-1 agonists. Blood pressure, cholesterol levels, C-reactive protein, and insulin resistance may improve in patients treated with exenatide. The direct effect of GLP-1 on cardiac myocytes and vascular smooth muscle has been an active area of investigation. Infusions of... Weighing in on blood pressure Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0003-zAuthors Arya M. Sharma Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Hypertension Reports) The BEAUTIFUL study: Is heart rate reduction a new therapeutic principle? Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0009-6Authors Frank EnseleitFrank T. Ruschitzka Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Hypertension Reports) ONTARGET: How much RAS inhibition is enough? Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-009-0002-0Authors Alan B. Weder Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Hypertension Reports) Literature alert Content Type Journal ArticleDOI 10.1007/s11906-009-0001-1 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Hypertension Reports) A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae This report provides a comprehensive review of studies exploring NPPA polymorphisms in relation to hypertension and hypertension-related outcomes. Content Type Journal ArticleDOI 10.1007/s11906-009-0008-7Authors Amy I. Lynch, University of Minnesota Medical School Department of Laboratory Medicine and Pathology Mayo Mail Code 609, 420 Delaware Street SE Minneapolis MN 55455 USASteven A. ClaasDonna K. Arnett Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Hypertension Reports) Hypertension in women Abstract  Systolic blood pressure is higher in African American and Hispanic women older than 60 and in white women older than 70 than it is in men. Coupled with their longer survival, elderly women have higher hypertension prevalence rates, particularly for isolated systolic hypertension. Hemodynamic characteristics differ by sex for premenopausal women and age-matched men, but these differences lessen after menopause. This transition may result from hormonal or metabolic alterations, including weight gain and tissue adiposity, which are common after menopause. Clinical trials enrolling large numbers of women support the benefits of treatment to reduce cardiovascular events and mortality. The trend to enroll subjects with several comorbidities and thereby increase event ra... Non-pressure-related effects of dietary sodium Abstract  After the demonstration of a positive correlation between sodium intake and arterial pressure in large population studies, the effect of short-term reduction in sodium intake demonstrated the efficacy of this nonpharmacologic therapy. In addition, a positive relation between urinary sodium (the most reliable estimate of salt intake) and left ventricular hypertrophy was found; and in recent years it was shown that cardiovascular morbidity clearly progressed with increasing sodium intake, despite one contradictory study. The role of non-pressure-related effects of dietary sodium is discussed in order to bring more arguments for a large-scale attempt to reduce sodium intake by 30% to 50%. Content Type Journal ArticleDOI 10.1007/s11906-009-0004-yAuthors Guilhem du... Vascular insulin resistance: A potential link between cardiovascular and metabolic diseases This article reviews experimental and clinical data elucidating the physiologic and pathophysiologic role of insulin in the vasculature and the mechanisms contributing to the development of vascular and metabolic diseases. Content Type Journal ArticleDOI 10.1007/s11906-009-0010-0Authors Ivonne Hernandez SchulmanMing-Sheng Zhou, University of Miami Miller School of Medicine, Veterans Affairs Medical Center, Nephrology-Hypertension Section Vascular Biology Institute 1201 Northwest 16th Street, Room A-1009 Miami FL 33125 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 11 Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Hypertension Reports) Angiotensin vaccination: What is the prospect of success? Abstract  Over many decades, several attempts have been made to treat hypertension using a vaccination strategy to inhibit the renin-angiotensin system. Renin vaccination successfully inhibited renin activity and reduced blood pressure in animal models, but caused autoimmune disease of the kidney. By contrast, most previous studies of angiotensin vaccination failed to reduce blood pressure in animal models, despite producing high titers of antibodies that prevented the pressor response to exogenous angiotensins. Angiotensin vaccination is being revisited as a strategy for treating hypertension, in the hope that new conjugates of angiotensin I and angiotensin II will produce antibodies of sufficient titer and affinity to reduce blood pressure in patients with hypertension. A... The hypertension peril: Lessons from CETP inhibitors Abstract  Pharmacologic inhibitors of the cholesteryl ester transfer protein (CETP) are capable of increasing HDL cholesterol by 50% to 100% in humans. Despite intriguing antiatherogenic effects of CETP inhibition in animal models of atherosclerosis, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial investigators observed an excess of cardiovascular and noncardiovascular morbidity and mortality associated with the use of the CETP inhibitor torcetrapib. This review summarizes available clinical and experimental data about potential underlying mechanisms. Content Type Journal ArticleDOI 10.1007/s11906-009-0014-9Authors Matthias Hermann, University Hospital Zürich Department of Cardiology Ramistrasse 100 CH-8091 Zürich Sw... Renal protective effect of renin inhibition Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0088-9Authors Theodore A. Kotchen Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Perioperative control of hypertension: When will it adversely affect perioperative outcome? Abstract  Much has been published about the impact of treatment on adverse outcomes in patients with cardiovascular diseases. Hypertension is an extremely common condition affecting a significant percentage of the world population. Although care guidelines exist for the medical patient with raised blood pressure, there are no accepted guidelines for the preoperative evaluation and perioperative care of the patient with hypertension who undergoes noncardiac surgery. Of particular importance are defining at-risk groups of patients, and the indications for cancellation to treat and hence reduce this risk. This review examines the interactions between hypertension, drug therapies, anesthesia, and adverse outcomes in these patients. Recommendations for identifying patients at gr... Endothelin antagonist for the treatment of resistant hypertension Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0080-4Authors Steven A. Atlas Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Leptin and mechanisms of endothelial dysfunction and cardiovascular disease This report reviews pertinent literature on leptin-mediated endothelial dysfunction, leptin-mediated sympathetic activation, and leptin as a significant perivascular adipose-derived factor. Content Type Journal ArticleDOI 10.1007/s11906-008-0082-2Authors Jarrod D. Knudson, Baylor College of Medicine Department of Pediatrics One Baylor Plaza Houston TX 77030 USAGregory A. PayneLéna BorbouseJohnathan D. Tune Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Aliskiren combined with losartan: Thor?s hammer or Sigurd?s sword? Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0081-3Authors Thomas R. LuxHeinrich Taegtmeyer Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Impaired cardiac function in leptin-deficient mice This article briefly reviews leptin?s physiologic role in cardiomyocyte structure and function and how leptin deficiency or disrupted signaling may trigger cardiac functional and morphologic abnormalities. Content Type Journal ArticleDOI 10.1007/s11906-008-0084-0Authors Jun Ren, Fourth Military Medical University Department of Physiology Xi?an ChinaHeng Ma Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) The PAT family of lipid droplet proteins in heart and vascular cells Abstract  Cytoplasmic lipid droplets (LDs) are organelles in which cells store neutral lipids for use as an energy source in times of need, but they also play important roles in the regulation of key metabolic processes. Although LDs are essential for normal cell function, excess accumulation of intracellular lipid is associated with several metabolic diseases, including obesity, type 2 diabetes, and atherosclerosis. The function of LDs is regulated by their associated proteins, including the members of the PAT family: perilipin, adipophilin/adipose differentiation-related protein, tail-interacting protein 47, S3-12, and OXPAT/myocardial LD protein/lipid-storage droplet protein 5. In this review we discuss the PAT proteins in two cardiovascular contexts: 1) in the atheroscl... Cardiomyocyte apoptosis in animal models of obesity This article critically reviews studies conducted in animal models of obesity that have expanded our understanding of the mechanisms of cardiomyocyte apoptosis and their role in various obesity-associated cardiovascular diseases. Content Type Journal ArticleDOI 10.1007/s11906-008-0085-zAuthors Premal S. TrivediLili A. Barouch, Johns Hopkins University Division of Cardiology 720 Rutland Avenue, Ross 1050 Baltimore MD 21205 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Mediators of sympathetic activation in metabolic syndrome obesity Abstract  The metabolic syndrome represents a major public health burden because of its high prevalence in the general population and its association with cardiovascular disease and type 2 diabetes. Accumulated evidence based on biochemical, neurophysiologic, and indirect measurements of autonomic activity indicate that visceral obesity and the metabolic syndrome are associated with enhanced sympathetic neural drive and vagal impairment. The mechanisms linking metabolic syndrome with sympathetic activation are complex and not completely understood, and cause-effect relationships need further clarification from prospective trials. Components of the metabolic syndrome that may directly or indirectly enhance sympathetic drive include hyperinsulinemia, leptin, nonesterified fat... Aldosterone and CKD in metabolic syndrome Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11906-008-0078-yAuthors Toshiro Fujita, University of Tokyo Department of Nephrology and Endocrinology 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8655 Japan Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Treating hypertension prevents heart failure Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11906-008-0079-xAuthors M. Gary Nicholls, University of Otago-Christchurch, Christchurch Hospital Department of Medicine PO Box 4345 Christchurch New Zealand Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Resistant hypertension and hyperaldosteronism Abstract  Resistant hypertension is defined as blood pressure that remains uncontrolled in spite of ? 3 antihypertensive medications at effective doses, ideally including a diuretic. Although exact prevalence is unknown, clinical trials suggest that 20% to 30% of study participants are resistant. Hyperaldosteronism, obesity, refractory volume expansion, and obstructive sleep apnea are common findings in resistant hypertension patients. Multiple studies indicate that primary aldosteronism (PA) is common (? 20%) in patients with resistant hypertension. Screening for PA is recommended for most patients with resistant hypertension, ideally by measurement of 24-hour urinary aldosterone excretion, or by the plasma aldosterone/plasma renin activity ratio. Successful treatment ... Genetic determinants of hypertension: An update Abstract  Hypertension represents a global public health burden. In addition to the rarer Mendelian forms of hypertension, classic genetic studies have documented a significant heritable component to the most common form, essential hypertension (EH). Extensive efforts are under way to elucidate the genetic basis of this disease. Recently, a new form of Mendelian hypertension has been identified, pharmacogenetic association studies in hypertensive patients have identified novel gene-by-drug interactions, and the first genome-wide association studies of EH have been published. New findings in consomic and congenic rat models also offer new clues to the genetic architecture of this complex phenotype. In this review, the authors summarize and evaluate the most recent findings r... Vaccination: A novel strategy for inhibiting the renin-angiotensin-aldosterone system Abstract  Immunologic approaches to renin-angiotensin-aldosterone system (RAAS) inhibition have been studied for more than 50 years. In animal models, vaccination against renin was effective but resulted in fatal autoimmune renal disease; vaccines directed at small peptides including angiotensin I and II and a segment of the AT1 receptor reduced blood pressure (BP) without causing autoimmune disease. In humans, angiotensin I vaccination did not reduce BP. More promising is the AngQb vaccine, which uses an immunization technology involving conjugation of angiotensin II to virus-like particles. In a phase 2 trial, hypertensive patients vaccinated with 300 ?g showed a difference of 9.0/4.0 mm Hg from baseline in mean daytime ambulatory BP after 14 weeks (P = 0.015 for systolic... Effect of angiotensin II type 1 receptor blockers in patients with self-monitored morning hypertension Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0087-xAuthors George MansourJanette Mansour Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Hypertension Reports) Insulin resistance and blood pressure Abstract  Insulin resistance, cardiometabolic syndrome, and hypertension are common health problems with significant consequences for individuals and society. The pathogenesis of these disorders is complex and not fully understood. In this article we review the current knowledge about the effects of lifestyle modification and pharmacologic antihypertensive agents on insulin resistance and hypertension. Content Type Journal ArticleDOI 10.1007/s11906-008-0059-1Authors Sonya AddisonSameer StasMelvin R. HaydenJames R. Sowers, University of Missouri School of Medicine, D109 HSC Diabetes Center, One Hospital Drive, Harry S. Truman VA Medical Center Diabetes and Cardiovascular Center Columbia MO 65212 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN... Treating prehypertension: A review of the evidence Abstract  Although the term ?prehypertension? has been challenged by some, its use to define people with systolic blood pressure (BP) between 120 and 139 mm Hg and/or diastolic pressures between 80 and 89 mm Hg has gained general acceptance. The category includes as many people as the number who have hypertension, defined as blood pressure of 140/90 or above. Such people are clearly at an increased risk of cardiovascular damage compared with people with BPs below 120/80 mm Hg. The major unresolved issue is the appropriate management of such patients. Two trials have attempted to document the value of short-term drug therapy to prevent the progression of BP to overt hypertension, but no outcome studies are currently available. Content Type Journal ArticleDOI 10.1007/s1... ONTARGET for hypertension or not? Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0056-4Authors Thomas D. Giles Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Hypertension Reports) Advances in the understanding of eclampsia Abstract  Preeclampsia, a serious hypertensive complication of pregnancy characterized by new-onset hypertension and proteinuria after midpregnancy, is a multisystem disorder that often involves the central nervous system. Neurologic signs and symptoms include hyperreflexia, headaches, visual disturbance, seizures, and cerebral hemorrhage. Eclampsia?new-onset seizures in the setting of preeclampsia?usually occurs before or within 48 hours of delivery, but can present as late as 1 month postpartum (late postpartum eclampsia). Magnesium sulfate is the drug of choice to prevent and treat eclampsia, a recommendation validated through large, randomized, and placebo-controlled trials. This review describes the pathogenesis, clinical features, and treatment of eclampsia, focus... Direct renin inhibition: An analysis of possible benefits Abstract  The US Food and Drug Administration?s approval in March 2007 of aliskiren, the first commercially available direct renin inhibitor, for the treatment of hypertension met with great enthusiasm. Clinical trials have demonstrated it to be as effective as other commonly prescribed antihypertensive agents with few side effects. Preclinical studies in genetically manipulated rats have shown it to be effective in reversing angiotensin II-induced cardiac and renal damage. Despite the notable absence of human clinical data for this agent, many clinicians have touted aliskiren as the ideal agent to achieve additional suppression of the renin-angiotensin-aldosterone system (RAAS) as a means to reduce the morbidity and mortality of chronic diseases of the cardiovascular and... Race-based therapeutics Abstract  The issue of race in medicine is problematic. Race is not a physiologic grouping, and all persons of a given race do not necessarily share the same clinical phenotype or genetic substrate. Despite clear signals that certain risk factors and diseases vary as a function of race, translating those differences into race-based therapeutics has been awkward and has done little to change the natural history of cardiovascular disease as it affects special populations. Among the varied special populations, the African American population appears to have the most significant and adverse variances for cardiovascular disease as well as worrisome signals that drug responsiveness varies. Recent guideline statements have now acknowledged certain treatment options that are most a... Dopamine receptors and hypertension Abstract  Dopamine plays an important role in regulating renal function and blood pressure. Dopamine synthesis and dopamine receptor subtypes have been shown in the kidney. Dopamine acts via cell surface receptors coupled to G proteins; the receptors are classified via pharmacologic and molecular cloning studies into two families, D1-like and D2-like. Two D1-like receptors cloned in mammals, the D1 and D5 receptors (D1A and D1B in rodents), are linked to adenylyl cyclase stimulation. Three D2-like receptors (D2, D3, and D4) have been cloned and are linked mainly to adenylyl cyclase inhibition. Activation of D1-like receptors on the proximal tubules inhibits tubular sodium reabsorption by inhibiting Na/H-exchanger and Na/K-adenosine triphosphatase activity. Reports exist of de... Treating very elderly hypertensive patients is rewarding: The HYVET results Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0055-5Authors Giuseppe ManciaGuido Grassi Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Hypertension Reports) Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients? Abstract  The Heart Outcomes Prevention (HOPE) trial was the first to demonstrate the benefits of the angiotensin-converting enzyme (ACE) inhibitor ramipril for high-risk cardiovascular patients. Whether the cardioprotective effects seen in HOPE and other trials are specific to distinct ACE inhibitors remains controversial. Evidence of a lack of class effect for ACE inhibitors has policy and financial implications related to reference pricing by insurers and inclusion on pharmacy formularies. Because head-to-head trials comparing the different ACE inhibitors are unforeseen, clinicians and administrators must rely on secondary-level data and observational studies. Only a handful of studies have sought to address the dispute over a class effect among ACE inhibitors, which is ... Evidence for benefits of angiotensin receptor blockade beyond blood pressure control Abstract  Elevated levels of angiotensin II result in oxidative stress and endothelial dysfunction, which initiate atherogenic pathologic processes that are important in cardiovascular disease development. Angiotensin II induces its deleterious effects primarily through the type 1 receptor; these effects are inhibited by angiotensin II receptor blockers (ARBs) directly at the receptor level. Angiotensin II may potentiate protective mechanisms through stimulation of the type 2 receptor, which is not blocked by ARBs. Accumulating data suggest that blockade of angiotensin II production or activity provides vascular and cardioprotective benefits, such as reduction of atrial fibrillation, acute myocardial infarction, and heart failure events. Moreover, blockade of the renin-angi... Insulin resistance, microalbuminuria, and chronic kidney disease Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11906-008-0046-6Authors Pantelis A. Sarafidis, AHEPA University Hospital, Aristotle University of Thessaloniki Section of Nephrology and Hypertension, First Department of Medicine St. Kiriakidi 1 54636 Thessaloniki GreeceLuis M. Ruilope Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Hypertension Reports) Literature alert Content Type Journal ArticleDOI 10.1007/s11906-008-0047-5 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Hypertension Reports) ADVANCE in management of vascular complications of diabetes Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0048-4Authors Helmy M. Siragy Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Hypertension Reports) A new mandate for treating hypertension in the elderly Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0049-3Authors Michael A. Weber Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Hypertension Reports) Pharmacologic considerations in the positioning of ?-blockers in antihypertensive therapy Abstract  ?-Blockers have been used to treat hypertension for decades, either as monotherapy or combined with other antihypertensive agents, primarily diuretics, often as fixed-dose combination products. Although ?-blockers can lower blood pressure in most patients, outcomes data with these drugs have been disappointing and their value for patients without ?compelling indications? has been questioned recently. The early ?-blockers had significant pharmacologic shortcomings; however, later-generation ?-blockers have distinctive and presumably better pharmacologic profiles. The most recently introduced drugs, the vasodilating ?-blockers carvedilol and nebivolol, are now being broadly evaluated as to their efficacy and tolerability in clinical practice. Content Type... Should chlorthalidone be the diuretic of choice for antihypertensive therapy? Abstract  For decades, diuretic therapy has been a cornerstone in treating hypertension, an approach supported by multiple randomized controlled trials demonstrating reduced morbidity and mortality from cardiovascular events. Yet controversy persists regarding the potential detrimental metabolic effects and side effects of diuretic agents. Within the risk-benefit debates about diuretic therapy is a second dialogue regarding the best thiazide or thiazidelike agent to prescribe. Proponents of chlorthalidone emphasize the demonstrated reductions in cardiovascular events reported from multiple classic trials and its longer half-life, whereas opponents point to its limited availability in low-dose forms and comparable favorable results from hydrochlorothiazide-based therapy to d... Prehypertension: Risk stratification and management considerations Abstract  Approximately 37% of US adults are prehypertensive; about 31 million have blood pressures in the range of 130?139/85?89 mm Hg. These stage 2 prehypertensives have threefold greater risk for developing hypertension and twofold higher risk for cardiovascular events than normotensives. Lifestyle changes only are recommended for most prehypertensives, but evidence for community-wide effectiveness is limited. Projected numbers needed to treat to prevent a cardiovascular event are similar for stage 2 prehypertension and stage 1 hypertension when both groups are matched for concomitant risk factors. However, no clinical trials document that pharmacotherapy reduces cardiovascular events in stage 2 prehypertension. The Trial of Preventing Hypertension demonstrated that... Literature alert Content Type Journal ArticleDOI 10.1007/s11906-008-0063-5 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 5 / October, 2008 (Source: Current Hypertension Reports) Telmisartan, ramipril, or both in patients at high risk for vascular events Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0064-4Authors Donald G. Vidt Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 5 / October, 2008 (Source: Current Hypertension Reports) ONTARGET study of telmisartan, ramipril, or both in high-risk patients Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0065-3Authors C. Venkata S. Ram Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 5 / October, 2008 (Source: Current Hypertension Reports) Management of hypertension in patients with coronary artery disease Abstract  Hypertension is present in three of four patients with coronary artery disease (CAD) but remains largely uncontrolled in most patients. Treating hypertension in these patients is complicated by the concern of precipitating coronary ischemia when diastolic blood pressure (DBP) is reduced excessively. However, an emerging body of evidence from recent clinical trials in high-risk hypertensive patients with or without CAD demonstrated the benefit of intensive drug therapy, even when DBP fell much lower than 80 mm Hg, in terms of reducing cardiovascular events and progression of coronary and carotid atherosclerosis. Accordingly, the American Heart Association has now set the target BP goal to less than 130/80 mm Hg in hypertensive patients with CAD. Given the enormous ... Recent advances in automated blood pressure measurement Abstract  During the past 15 years, clinical outcome studies have consistently reported that home and 24-hour ambulatory blood pressure recordings provide a significantly better measure of cardiovascular risk than do manual blood pressure readings taken in the office or clinic. The advent of automated sphygmomanometers that record blood pressure with the patient alone in the examining room will be the next major change in our approach to recording blood pressure. These automated devices virtually eliminate the white coat response and their readings correlate significantly better with the ambulatory blood pressure compared with manual office blood pressure readings. The principal finding from recent research into automated blood pressure measurement is that the presence of a... Clinical trials report Content Type Journal ArticleDOI 10.1007/s11906-008-0072-4Authors George L. Bakris Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 5 / October, 2008 (Source: Current Hypertension Reports) Behavioral cardiology: Recognizing and addressing the profound impact of psychosocial stress on cardiovascular health Abstract  Psychosocial stress exerts independent adverse effects on cardiovascular health. The INTERHEART study reported that psychosocial stress accounted for approximately 30% of the attributable risk of acute myocardial infarction. Prospective studies consistently indicate that hostility, depression, and anxiety are related to increased risk of coronary heart disease and cardiovascular death. A sense of hopelessness, in particular, appears to be strongly correlated with adverse cardiovascular outcomes. Time urgency and impatience have not been consistently related to risk of coronary disease, but increase the likelihood of developing hypertension. Psychosocial stress appears to adversely affect autonomic and hormonal homeostasis, resulting in metabolic abnormalities, inf... Hypertension management in patients with chronic kidney disease Abstract  Hypertension is one of the major risk factors for the development and progression of chronic kidney disease. The loss of renal function leads to impaired renal autoregulation and renders the kidney vulnerable to the damaging effects of uncontrolled hypertension. Mounting evidence indicates that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers slow the progression of chronic kidney disease through effects beyond lowering blood pressure. Studies are needed to determine whether high doses of the single agent or combination therapy is most effective in providing renal protection. Urinary protein excretion is a useful tool for monitoring and titrating therapy to maximize renal protection. Changes in the serum creatinine concentration and hyper... New guidelines of the European society of hypertension Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11906-008-0062-6Authors Julian SeguraLuis M. Ruilope, Hospital 12 de Octubre Hypertension Unit Av. Córdoba s/n 28041 Madrid Spain Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 5 / October, 2008 (Source: Current Hypertension Reports) Are we ?ONTARGET? yet with regard to optimal antihypertensive regimens? Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11906-008-0071-5Authors Matthew R. Weir Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 5 / October, 2008 (Source: Current Hypertension Reports) Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? Abstract  Examination of the large-scale drug-versus-drug trials suggests that the initial drug choice is of token importance and that better blood pressure control is the primary determinant of superior outcomes. In pooled analyses, the achieved blood pressure is similar for older and less expensive drugs, such as thiazide-type diuretics, and for newer and more costly agents, such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and calcium-channel blockers. If blood pressure-independent differences favoring one antihypertensive drug class over another truly exist, they have been singularly difficult to uncover with any consistency. Considering that multidrug therapy is required in the majority of patients with hypertension, the debate as to whic... Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Abstract  Recently, clinical trial data showed that rapid attainment of goal blood pressure (BP) reduces the risk for cardiovascular disease (CVD) events. It is unknown whether patient characteristics linked to the magnitude of CVD risk influence the speed of BP control. Time to attain goal systolic BP (SBP) in Kaplan-Meier survival curves was contrasted for strata of baseline characteristics and intensity of hypertension treatment. Survival analyses showed that albuminuria, diabetes, increased body mass index, millimeters of mercury above Joint National Committee (JNC) SBP goal, higher Framingham risk score, older age, depressed estimated glomerular filtration rate, and greater intensity of antihypertensive drug treatment all predicted slower JNC SBP goal attainment (P &lt... Does socioeconomic status affect blood pressure goal achievement? Abstract  Hypertension is a major cause of disease burden in all racial, ethnic, and socioeconomic groups in developing and developed regions and countries. Differences in blood pressure likely begin early in life and reflect a complex relationship of biologic, genetic, social, and environmental interactions. The relationship between socioeconomic status and hypertension is complex and difficult to measure. Instituting lifestyle changes for the primary prevention and treatment of hypertension among the general population would decrease prevalence, improve blood pressure control, and be effective in eliminating many socioeconomic differences in risk factors for cardiovascular disease. Health care providers can potentially impact blood pressure control by incorporating knowle... Pharmacologic modulation of ACE2 expression Abstract  Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension. Content Type Journal ArticleDOI 10.1007/s11906-008-0076-0Authors María José SolerClara BarriosRaymond OlivaDaniel Batlle, Northwestern University Division of Nephrology and Hypertension, Department of Medicine, Feinberg School of Medicine 320 East Superior Chicago IL 60611 US... Renin receptor blockade: A better strategy for renal protection than renin-angiotensin system inhibition? Abstract  Prorenin and renin bind to a 350-amino acid protein called the (pro)renin receptor, which is present on the surface and functions intracellularly. When the receptor?s N terminus binds either prorenin or renin, intracellular signaling occurs via extracellular-regulated kinases, which can result in plasminogen activator inhibitor and transforming growth factor-? production. Investigators have developed a novel decoy peptide, called the handle-region peptide (HRP), which obviates binding of prorenin to the receptor. HRP has successfully inhibited diabetic nephropathy in rats and in angiotensin receptor-deleted mice, and has blocked fibrosis in the hearts of spontaneously hypertensive rats. The same researchers developed a transgenic (pro)renin receptor-expressing ... Clinical trials report Content Type Journal ArticleDOI 10.1007/s11906-008-0033-yAuthors Barry J. Materson Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Prevention of atrial fibrillation in hypertension Abstract  Hypertensive patients have an increased risk of developing atrial fibrillation (AF), which increases cardiovascular morbidity and mortality in this population. Primary prevention is a new strategy in treating AF; previously, it was more common to focus on preventing adverse outcomes and controlling the arrhythmia?s rate and rhythm. In this review, we consider the possible preventive effects of antihypertensive treatment on new-onset AF seen in recent trials, especially with blockers of the renin-angiotensin system (RAS). Several secondary analyses of large, randomized trials regarding hypertension and heart failure have shown promising results with benefits beyond the expected blood pressure-lowering effect. A few prospective studies on prevention of AF recurrenc... Now that we have a direct renin inhibitor, what should we do with it? Abstract  Aliskiren is the first renin inhibitor to be licensed for use as an antihypertensive drug in both the United States and Europe. Opinions vary considerably concerning the future of aliskiren and renin inhibition. Some experts argue that renin inhibitors should only be prescribed when less expensive blockers of the renin-angiotensin system (RAS), with established effects on morbidity and mortality, are not tolerated or have failed to reduce blood pressure effectively. Others propose that because renin is a highly specific catalyst for the rate-limiting step of the RAS, renin inhibitors have the potential to supersede angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as the preferred inhibitors of the cascade in patients with particular patho... Hypertension and hepatic steatosis Abstract  Hepatic steatosis (fatty liver) is increasingly recognized as a major component of the metabolic (insulin resistance) syndrome. It can progress to cirrhosis and hepatocellular carcinoma, leading to liver-related mortality. Increasing evidence shows a significant association between hepatic steatosis and hypertension; both are linked to the metabolic syndrome. This review discusses the evidence to support this association, and reviews the diagnosis and management of hepatic steatosis. Content Type Journal ArticleDOI 10.1007/s11906-008-0035-9Authors Matthew J. BrookesTariq H. IqbalBrian T. Cooper, City Hospital Gastroenterology Unit Dudley Road Birmingham B18 7QH UK Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Vo... The angiotensin II type 2 receptor: What is its clinical significance? This article reviews recent experimental and clinical data elucidating the role of the AT2 receptor in cardiovascular and renal homeostasis. Content Type Journal ArticleDOI 10.1007/s11906-008-0036-8Authors Ivonne Hernandez Schulman, University of Miami Miller School of Medicine Nephrology-Hypertension Section, Veterans Affairs Medical Center 1201 Northwest 16 Street, Room A-1009 Miami FL 33125 USALeopoldo Raij Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Angiotensin-(1-7) as an antihypertensive, antifibrotic target Abstract  Over the past two decades, enormous progress has been made in understanding the possible physiological significance of alternate renin-angiotensin system processing pathways and angiotensin fragments, such as angiotensin (Ang)-(1-7). Evidence from in vivo and ex vivo studies in humans and various animal models suggests a possible role for this heptapeptide in blood pressure regulation, although the mechanisms involved are most likely indirect, involving some combination of bradykinin and nitric oxide signaling. In contrast, a growing body of in vivo and in vitro evidence supports direct cardioprotective (antihypertrophic, antifibrotic) actions of Ang-(1-7). Here, we review key studies investigating the blood pressure and tissue-protective roles of Ang-(1-7), and s... Using health information technology to improve hypertension management Abstract  High-quality medical care requires implementing evidence-based best practices, with continued monitoring to improve performance. Implementation science is beginning to identify approaches to developing, implementing, and evaluating quality improvement strategies across health care systems that lead to good outcomes for patients. Health information technology has much to contribute to quality improvement for hypertension, particularly as part of multidimensional strategies for improved care. Clinical reminders closely aligned with organizational commitment to quality improvement may be one component of a successful strategy for improving blood pressure control. The ATHENA-Hypertension (Assessment and Treatment of Hypertension: Evidence-based Automation) system is a... Literature alert Content Type Journal ArticleDOI 10.1007/s11906-008-0031-0 Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Masked hypertension in children and adolescents Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11906-008-0030-1Authors Empar Lurbe, Consorcio Hospital General, University of Valencia Pediatrics Department Avda Tres Cruces 2 46014 Valencia Spain Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Clinical trials report Content Type Journal ArticleDOI 10.1007/s11906-008-0032-zAuthors Franz H. Messerli Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Neurohormonal regulation of the sympathetic nervous system: New insights into central mechanisms of action Abstract  To regulate blood pressure, the brain controls circulating hormones, which influence the brain by binding to brain neurons that lie outside the blood-brain barrier. Recent work has demonstrated that ?cardiovascular? hormones are synthesized and released in the brain as neurotransmitters/neuromodulators and can, in some cases, signal through the blood-brain barrier. The renin-angiotensin system is a prototype for these newly appreciated mechanisms. The brain?s intrinsic reninangiotensin system plays an important role in blood pressure control. Angiotensin II in brain neurons affects other neurons both through activation of angiotensin receptors and via generation of nitric oxide and reactive oxygen molecules. Similarly, angiotensin in blood vessels activates ... Obesity, sleep apnea, aldosterone, and hypertension Abstract  The pathogenesis of hypertension associated with obesity is unclear. This review provides evidence supporting excess visceral fat as an early aspect, and obstructive sleep apnea and elevated levels of aldosterone as factors closer to hypertension in the mechanistic chain. Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here. Possible therapeutic interventions addressing the hypertension associated with obesity are briefly mentioned. Content Type Journal ArticleDOI 10.1007/s11906-008-0042-xAuthors Theodore L. Goodfriend, William S. Middleton Memorial Veterans Hospital Research Service 2500 Overlook Terrace Madison WI 53705 USA Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN... Clinical trials report Content Type Journal ArticleDOI 10.1007/s11906-008-0039-5Authors Kathleen H. BerecekDenise Kimbrough Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Clinical trials report Content Type Journal ArticleDOI 10.1007/s11906-008-0040-zAuthors Eduardo PimentaSuzanne Oparil Journal Current Hypertension ReportsOnline ISSN 1534-3111Print ISSN 1522-6417 Journal Volume Volume 10 Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Hypertension Reports) Mineralocorticoid antagonism and cardiac hypertrophy Abstract  Aldosterone provides circulatory support by promoting reabsorption of sodium in exchange for potassium in the kidney. Mineralocorticoid receptors (MRs) are found in nonepithelial (vessel, heart, and brain) and epithelial tissues. Excess aldosterone may exert harmful effects by provoking hypertrophy and fibrosis in the cardiovascular system, thus contributing to reduced vascular compliance and increased ventricular stiffness. Primary aldosteronism is the most common cause of mineralocorticoid-induced hypertension, and MR antagonism offers the best prospect for achieving therapeutic goals. MR blockade also ameliorates pathological changes in the heart in the setting of low-aldosterone hypertension. The beneficial cardiac effects of MR antagonists are likely attribut...

Hypertension Medications guide

Hypertension Medications Information

Hypertension Medications Such As Combipres Have Been Proven To Be Effective

In case you are looking for effective hypertension medications then it would be worth checking out one that goes by the name of Combipres that is often prescribed to treat high blood pressure or hypertension. In fact, Combipres is a combination medication that contains both chlorthalidone and also clonidine which work well with each other and is effective in controlling hypertension. Know How Combipres Works If you would like to know more about how Combipres works, it is worth looking at each of its components in more detail so that you can get a clearer picture of the effectiveness of using Combipres. The clonidine component in this hypertension medication makes sure that the blood-carrying vessels are made to relax which in turn helps in regulating the blood that is being pumped from the heart to other parts of the body and it also ensures that there is very little resistance and thus the heart is not put under any additional stress. On the other hand, the chlorthalidone component of this hypertension medication helps in increasing the salt and water content in the body and thus there are no problems such as swelling and in fact the chlorthalidone works much like a diuretic and replenishes

Digital High Low Blood Pressure Wrist Monitor Machine

US $29.95 (0 Bid)
Sale Ends: Wednesday Mar-10-2010 8:26:15 PST
Place a Bid

Prestige Medical Blood Pressure Kit usd once with bag

US $10.00 (0 Bid)
Sale Ends: Wednesday Mar-10-2010 8:36:25 PST
Place a Bid

OMRON DELUXE blood pressure monitor NEW in BOX!

US $59.95
Sale Ends: Wednesday Mar-10-2010 8:53:56 PST
Buy It Now for only: US $59.95
Buy it Now

SFO Fully Automatic Arm Blood Pressure & Pulse Monitor

US $12.51 (8 Bids)
Sale Ends: Wednesday Mar-10-2010 8:59:23 PST
Place a Bid

NEW Fully Automatic Arm Cuff Blood Pressure Monitor

US $39.98
Sale Ends: Wednesday Mar-10-2010 9:07:13 PST
Buy It Now for only: US $39.98
Buy it Now

Digital Wrist Cuff Digital Blood Pressure Monitor NEW

US $0.99 (1 Bid)
Sale Ends: Wednesday Mar-10-2010 9:32:58 PST
Place a Bid

LIFESOURCE Blood Pressure Monitor w/ XL Large Arm Cuff

US $105.28
Sale Ends: Wednesday Mar-10-2010 9:37:49 PST
Buy It Now for only: US $105.28
Buy it Now

Blood Pressure Cuff Monitor w Stethoscope Educational

US $19.99
Sale Ends: Wednesday Mar-10-2010 10:00:18 PST
Buy It Now for only: US $19.99
Buy it Now

Digital Wrist Cuff Digital Blood Pressure Monitor NEW

US $9.99 (0 Bid)
Sale Ends: Wednesday Mar-10-2010 10:14:35 PST
Place a Bid

Set of 6 Relaxation CD's Can Help Lower Blood Pressure

US $8.83 (0 Bid)
Sale Ends: Wednesday Mar-10-2010 10:19:30 PST
Buy It Now for only: US $8.98
Place a Bid
Buy it Now

Kyolic Blood Pressure Formula 109 80 Caps, Kyolic

US $17.00
Sale Ends: Wednesday Mar-10-2010 10:26:00 PST
Buy It Now for only: US $17.00
Buy it Now

Digital Wrist Auto Blood Pressure Measure Meter Monitor

US $7.48 (0 Bid)
Sale Ends: Wednesday Mar-10-2010 11:10:55 PST
Buy It Now for only: US $8.98
Place a Bid
Buy it Now

Click here to View more from this Category >

Increasing Soda Consumption Fuels Rise in Diabetes, Heart Disease (HealthDay)
HealthDay - FRIDAY, March 5 (HealthDay News) --Increasing consumption of sugary soft drinks contributed to 130,000 new cases of diabetes, 14,000 new cases of heart disease and 50,000 more life-years burdened with heart disease in the last decade, a new U.S. study finds.
Processed Meat May Harm the Heart (HealthDay)
HealthDay - FRIDAY, March 5 (HealthDay News) -- Conventional wisdom has dictated that fat from red meat is a risk factor for heart disease, but a new analysis from Harvard researchers finds it's eating processed meat -- not unprocessed red meat -- that increases the risk for heart disease and even diabetes.
Blacks, Hispanics With Heart Failure Less Likely to Use Hospice (HealthDay)
HealthDay - MONDAY, March 8 (HealthDay News) -- Blacks and Hispanics with advanced heart failure are much less likely to turn to hospice care than whites, even though blacks in particular are more likely to develop the condition, a new report finds.
Air Travel Could Raise Risk for Heartbeat Irregularities (HealthDay)
HealthDay - THURSDAY, March 4 (HealthDay News) -- Air travel could raise the risk for experiencing heartbeat irregularities among older individuals with a history of heart disease, a new study suggests.
Australian ruling opens floodgates for Vioxx claims (AFP)
AFP - An Australian judge on Friday found arthritis drug Vioxx doubled the risk of heart attacks and was not fit for sale, opening the way for hundreds of lawsuits against US pharmaceutical giant Merck.
Newer Blood Test Predicts Diabetes, Heart Disease (HealthDay)
HealthDay - WEDNESDAY, March 3 (HealthDay News) -- The newer hemoglobin A1C test predicts diabetes as well as the traditional fasting blood sugar test, but it beats that old standard in predicting a patient's future risk of heart disease and stroke, new research shows.
Industry crackdown on salt could save U.S. billions (Reuters)
Reuters - Working with the food industry to cut salt intake by nearly 10 percent could prevent hundreds of thousands of heart attacks and strokes over several decades and save the U.S. government $32 billion in healthcare costs, U.S. researchers said on Monday.
Future Heart Disease May Be in Store for Obese Kids (HealthDay)
HealthDay - MONDAY, March 1 (HealthDay News) -- Obese children as young as 3 could harbor a warning sign that they're at risk of heart disease in the future, new research suggests.
Cutting Off Blood Flow Limits Damage During Heart Attack (HealthDay)
HealthDay - FRIDAY, Feb. 26 (HealthDay News) -- Cutting off the flow of blood to the arm by repeatedly inflating a blood pressure cuff appears to reduce the amount of tissue damaged during a heart attack, a new Danish study shows.
New Clues to Lupus' Link With Heart Disease (HealthDay)
HealthDay - FRIDAY, Feb. 26 (HealthDay News) -- An increase in certain types of immune system antibodies may contribute to the development of heart disease in people with active lupus, a new study finds.

the amount of salt and water that is normally lost by the body as a result of urinating. Other than that, this hypertension medication will work in a slightly different manner in different instances, and it actually depends to a large extent on the patient s own medical needs and therefore only the physician can decide on the efficacy of using this hypertension medication and that too only after having assessed the patient s medical history. In any case, hypertension medications are not usually prescribed when a person has liver problems, or suffers from allergies to sulfa, or have been diagnosed as suffering from other ailments such as kidney diseases and gout as well as diabetes, heart diseases, stroke and even high cholesterol. In the event that you are prescribed hypertension medications such as Combipres and you are suffering from any of the afore-mentioned ailments, then you would need to have your medical condition closely monitored while being given such form of treatment. Hypertension medications such as Combipres have been classified by the US Food and Drug Administration as being pregnancy risk category B which means that this hypertension medication does not have any significant negative effect on a pregnant woman s fetus, though if you are pregnant and using Combipres, you need to first of all inform your doctor to let him know of your pregnancy. In any case, hypertension medications such as Combipres are not recommended for use in children and also not in the case of nursing mothers. The bottom line is that you won t go wrong if you try using Combipres because it is hypertension medication that has a history of helping in improving a person s hypertension problem, although at the same time it should only be used very cautiously.

Hypertension & High Blood Pressure Articles..

Can Massage Help Hypertension
We know that hypertension is a condition that occurs when a person’s blood pressure has elevated too high. There are actually various different levels of hypertension and it is a condition that Read more...

Understanding Cardiovascular Disease And Hypertension
The Link Between Cardiovascular Disease And Hypertension You must be aware that hypertension is often called the silent killer" and not in vain. There is a definite link between cardiovascular Read more...